- Home
- MLYS vs RVNC Comparison
MLYS vs RVNC Comparison
Compare MLYS & RVNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLYS
- RVNC
- Stock Information
- Founded
- MLYS 2019
- RVNC 1999
- Country
- MLYS United States
- RVNC United States
- Employees
- MLYS N/A
- RVNC N/A
- Industry
- MLYS Biotechnology: Pharmaceutical Preparations
- RVNC Biotechnology: Pharmaceutical Preparations
- Sector
- MLYS Health Care
- RVNC Health Care
- Exchange
- MLYS Nasdaq
- RVNC Nasdaq
- Market Cap
- MLYS 590.3M
- RVNC 599.6M
- IPO Year
- MLYS 2023
- RVNC 2014
- Fundamental
- Price
- MLYS $13.99
- RVNC $3.61
- Analyst Decision
- MLYS Strong Buy
- RVNC Buy
- Analyst Count
- MLYS 2
- RVNC 10
- Target Price
- MLYS $30.00
- RVNC $10.86
- AVG Volume (30 Days)
- MLYS 152.5K
- RVNC 1.6M
- Earning Date
- MLYS 11-12-2024
- RVNC 11-19-2024
- Dividend Yield
- MLYS N/A
- RVNC N/A
- EPS Growth
- MLYS N/A
- RVNC N/A
- EPS
- MLYS N/A
- RVNC N/A
- Revenue
- MLYS N/A
- RVNC $251,178,000.00
- Revenue This Year
- MLYS N/A
- RVNC $20.36
- Revenue Next Year
- MLYS N/A
- RVNC $31.66
- P/E Ratio
- MLYS N/A
- RVNC N/A
- Revenue Growth
- MLYS N/A
- RVNC 40.23
- 52 Week Low
- MLYS $5.85
- RVNC $2.30
- 52 Week High
- MLYS $16.91
- RVNC $9.75
- Technical
- Relative Strength Index (RSI)
- MLYS 57.43
- RVNC 26.17
- Support Level
- MLYS $13.33
- RVNC $5.67
- Resistance Level
- MLYS $15.25
- RVNC $5.97
- Average True Range (ATR)
- MLYS 0.63
- RVNC 0.21
- MACD
- MLYS -0.01
- RVNC -0.07
- Stochastic Oscillator
- MLYS 59.25
- RVNC 0.72
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.
About RVNC Revance Therapeutics Inc.
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.